Skip to main content
. Author manuscript; available in PMC: 2012 Mar 8.
Published in final edited form as: Cancer Cell. 2011 Mar 8;19(3):333–346. doi: 10.1016/j.ccr.2011.01.037

Figure 1. MMP-2-specific CD4+ T cell responses in melanoma patients.

Figure 1

TILs from representative melanoma patient M186 (A) or from 31 unselected patients (B) were stimulated with the MMP-2 peptide pool (2μM) for 6h and assessed for cytokine production by intracellular staining. Percentage of secreting cells upon peptide stimulation was considered specific/positive when it exceeded by more than twofold the background (cytokine-secreting cells in the absence of stimulation) and had more than 0.5% of responding cells (after background subtraction) for at least one cytokine. See also Fig.S1 for MMP-2-derived peptides and patient survival analysis.